Additionally, the authors indicated a potential protective effect of anti-Th/To antibodies, which appeared capable of decreasing the cancer risk associated with anti-RNA pol III positivity; it was also noticed that nine patients, who produced both anti-hPOP1 and anti-RNA pol III antibodies, did not have cancer-associated SSc within 3 years. This evidence concerns the gene POP1 and systemic sclerosis.